AstraZeneca resumes clinical trials in United Kingdom after green signal

AstraZeneca resumes clinical trials in United Kingdom after green signal

In July, Zayed said that Egypt had secured 30 million doses of a promising British vaccine developed by Oxford University and AstraZeneca, a British-Swedish company specialised in the pharmaceutical and biopharmaceutical fields.

AstraZeneca issued a statement on Tuesday night saying the late-stage studies of the vaccine had been paused while the company investigated whether a patient's reported side effects were connected to the vaccine.

The proposed expansion would allow the companies to enroll people as young as 16 and people with chronic, stable HIV, hepatitis C and hepatitis B.

On Saturday morning, the pharmaceutical company announced they had received confirmation from the Medicines Health Regulatory Authority (MHRA) based on reports from independent committees and global regulators that it was safe to resume its large-scale, worldwide assessment.

The company said it could not disclose further medical information.

Trials of the Oxford vaccine, which has been licensed to AstraZeneca, resumed at the weekend after safety watchdogs gave it the go-ahead.

"We believe this pledge will help ensure public confidence in the rigorous scientific and regulatory process by which COVID-19 vaccines are evaluated and may ultimately be approved", the companies said in the statement.

Germany's BioNTech and US-based Pfizer are developing a nucleoside-modified messenger RNA vaccine candidate. But respite testing, all of them have not yet completed clinical trials. India is the manufacturing partner of the COVID-19 vaccine candidate named Covishield, developed jointly by the University of Oxford's Jenner Institute's and AstraZeneca. This was reportedly flagged because of a volunteer in the United Kingdom who had developed a potentially serious adverse reaction.

An AstraZeneca spokesperson confirmed the pause in vaccinations covered studies in the USA and other countries.

Australian Health Minister Greg Hunt has said there is "genuine cause for hope and optimism" that a coronavirus vaccine will be available in the first half of 2021.

The scenario as of now is - 180 vaccine candidates in pre-clinical or clinical trials, 35 of them in clinical trials, 8 in final stages, phase-3 of human trials.

The US pharma giant Pfizer Inc and BioNTech SE have sought permission from the US Food and Drug Administration to expand the enrolment of their Phase 3 COVID-19 vaccine trial to 44,000.

Related Articles